Event Cardio Group Inc (ECGI) 0.0620 $ECGI
Event Cardio Group Completes Sale of 2,500,000 Shares of Common Stock and Takes Back Right to Market Its NowCardio(TM) Monitoring Device in Canada
Marketwired - Tue Jun 21, 3:00PM CDT
NEW YORK, NY--(Marketwired - June 21, 2016) - Event Cardio Group, Inc. (OTCQB: ECGI), developer of medical diagnostic equipment for the detection and preventive treatment of high-risk diseases, announced that it sold to an accredited investor 2,500,000 shares of its common stock and warrants to purchase an additional 833,333 shares of the Company's common stock exercisable at US$0.25 per share for an aggregate purchase price of $375,000 or US$0.15 cents per share. The Company also sold to two other accredited investors an aggregate of 10,000,000 shares of the company's common stock and warrants to purchase an aggregate of 5,000,000 shares of common stock exercisable at US$0.25 per share for a total purchase price of $1,000,000.
Event Cardio Group Crosses Major Hurdle
Marketwire Canada - Wed Dec 09, 3:17PM CST
Event Cardio Group, Inc. (OTCQB: ECGI), a medical device company, is pleased to announce that its Ambulatory Arrhythmia Monitoring System, NowCardio(TM), has successfully completed its stage 2 audit of compliance to Canadian Medical Devices Conformity Assessment System (CMDCAS). The audit was conducted by a recognized registrar, BSI Group, and is a significant milestone towards both Health Canada and FDA certification. NowCardio(TM) is on track to receive regulatory certification and approvals by Health Canada in Q1 of 2016, and by FDA early in Q2 of 2016.
Event Cardio Group, Inc. Appoints Cancer Industry Veteran, Julie Singleton, as Chief Executive Officer of Its BreastCare Division
Marketwire Canada - Wed Sep 16, 3:00PM CDT
Event Cardio Group, Inc. (OTCQB: ECGI), a leader in the development of cardiac monitoring and early detection of high-risk diseases, today announced the appointment of Julie Singleton as Chief Executive Officer of its BreastCare Division and to the Company's board of directors. Ms. Singleton currently serves as Chief Executive Officer at MedPac Asia Pacific PTY Ltd, of Australia, exclusive South East Asia Distributor of ECGI's BreastCare DTS (R) and NowCardio.
Event Cardio Group Satisfies Short Term Financing Needs
Marketwired - Tue Sep 08, 3:00PM CDT
Event Cardio Group, Inc. (www.eventcardiogroup.com) (OTCQB: ECGI), a medical device company specializing in the detection and preventive treatment of high-risk diseases, is pleased to announce that it has received $185,000 in equity investments. Coupled with $110,000 which the Company received approximately three weeks ago, the Company now has sufficient financing to satisfy its requirement for immediate cash and complete the development of its NowCardio device.
Event Cardio Group Completes First $500,000 of $2,000,000 BreastCare DTS(TM) Distribution Agreement for Southern Asia
Marketwire Canada - Tue Apr 28, 3:00PM CDT
Event Cardio Group, Inc. (www.eventcardiogroup.com) (OTCQB: ECGI), a medical device company specializing in the detection and preventive treatment of high-risk diseases, is pleased to announce it has received the final $300,000 thereby completing the initial $500,000 stage of the $2,000,000 licensing agreement with MedPac Asia Pacific PTY Ltd, of Australia. MedPac received a Convertible Promissory Note and was granted the exclusive distribution rights for both BreastCare DTS(TM) and NowCardio(TM) products in their exclusive territory -- Australia, New Zealand, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Laos, Cambodia, Myanmar and Bangladesh. With the Philippines having the highest breast cancer mortality rate among the countries listed, the immediate focus will be to use pre-existing distribution channels to make the BreastCare DTS(TM) device available for consumers.
Event Cardio Group, Inc. Completes Next Step in Production of FDA-510k Cleared BreastCare DTS Device
Marketwired - Wed Apr 22, 3:00PM CDT
Event Cardio Group, Inc. (www.eventcardiogroup.com) (OTCQB: ECGI), a medical device company specializing in the detection and preventive treatment of high-risk diseases, is pleased to announce that Ceres Technologies, based in Saugerties, New York, (www.cerestechnologies.com) has begun manufacturing the BreastCare DTS(TM) device. With production of units underway the FDA Code of Federal Regulations Title 21 required filing for Good Manufacturing Practices is in process.
Event Cardio Group Signs $8,000,000 Investment Term Sheet With a Hong Kong Corporation
Marketwire Canada - Wed Mar 18, 3:00PM CDT
Event Cardio Group, Inc. (OTCQB: ECGI), a medical device company that specializes in the detection and preventive treatment of high-risk diseases, is pleased to announce it entered into an Investment Term Sheet with R.J. Capital Management, Ltd. The term Sheet calls for an investment of $4,000,000 for 20% of Event Cardio Group and an additional $4,000,000 contribution by R. J. Capital towards a joint venture which will have exclusive distribution and manufacturing rights for Event Cardio Group's FDA approved Breast Care DTS(TM) in China.
Event Cardio Group Closes First Tranche of $2,000,000 BreastCare DTS(TM) Distribution Agreement for Southern Asia
Marketwire Canada - Mon Mar 09, 3:00PM CDT
Event Cardio Group, Inc. (OTCQB: ECGI), a medical device company that specializes in the detection and preventive treatment of high-risk diseases, is pleased to announce it has completed the initial $500,000 stage of a $2,000,000 licensing agreement with MedPac Asia Pacific PTY Ltd, of Australia. MedPac invested $500,000 in Event Cardio Group for which it received a Convertible Promissory Note and was granted the exclusive distribution rights for both BreastCare DTS(TM) and NowCardio(TM) products in their exclusive territoriy -- Australia, New Zealand, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Laos, Cambodia, Myanmar and Bangladesh. With the Philippines having the highest breast cancer mortality rate among the countries listed, the immediate focus will be to use pre-existing distribution channels to make the BreastCare DTS(TM) device available for consumers.
Event Cardio Group Acquires Worldwide Rights to Now Cardio(TM), Advanced Cardiac Monitoring Device
Marketwired - Wed Nov 19, 4:10PM CST
Event Cardio Group, Inc. (OTCQB: ECGI), a medical device company, announced it has finalized its acquisition of full intellectual property (IP) and development rights for Now Cardio(TM), advanced cardiac monitoring device.
Event Cardio Group Completes Sale of 2,500,000 Shares of Common Stock and Takes Back Right to Market Its NowCardio(TM) Monitoring Device in Canada
Marketwired - Tue Jun 21, 3:00PM CDT
NEW YORK, NY--(Marketwired - June 21, 2016) - Event Cardio Group, Inc. (OTCQB: ECGI), developer of medical diagnostic equipment for the detection and preventive treatment of high-risk diseases, announced that it sold to an accredited investor 2,500,000 shares of its common stock and warrants to purchase an additional 833,333 shares of the Company's common stock exercisable at US$0.25 per share for an aggregate purchase price of $375,000 or US$0.15 cents per share. The Company also sold to two other accredited investors an aggregate of 10,000,000 shares of the company's common stock and warrants to purchase an aggregate of 5,000,000 shares of common stock exercisable at US$0.25 per share for a total purchase price of $1,000,000.
Event Cardio Group Crosses Major Hurdle
Marketwire Canada - Wed Dec 09, 3:17PM CST
Event Cardio Group, Inc. (OTCQB: ECGI), a medical device company, is pleased to announce that its Ambulatory Arrhythmia Monitoring System, NowCardio(TM), has successfully completed its stage 2 audit of compliance to Canadian Medical Devices Conformity Assessment System (CMDCAS). The audit was conducted by a recognized registrar, BSI Group, and is a significant milestone towards both Health Canada and FDA certification. NowCardio(TM) is on track to receive regulatory certification and approvals by Health Canada in Q1 of 2016, and by FDA early in Q2 of 2016.
Event Cardio Group, Inc. Appoints Cancer Industry Veteran, Julie Singleton, as Chief Executive Officer of Its BreastCare Division
Marketwire Canada - Wed Sep 16, 3:00PM CDT
Event Cardio Group, Inc. (OTCQB: ECGI), a leader in the development of cardiac monitoring and early detection of high-risk diseases, today announced the appointment of Julie Singleton as Chief Executive Officer of its BreastCare Division and to the Company's board of directors. Ms. Singleton currently serves as Chief Executive Officer at MedPac Asia Pacific PTY Ltd, of Australia, exclusive South East Asia Distributor of ECGI's BreastCare DTS (R) and NowCardio.
Event Cardio Group Satisfies Short Term Financing Needs
Marketwired - Tue Sep 08, 3:00PM CDT
Event Cardio Group, Inc. (www.eventcardiogroup.com) (OTCQB: ECGI), a medical device company specializing in the detection and preventive treatment of high-risk diseases, is pleased to announce that it has received $185,000 in equity investments. Coupled with $110,000 which the Company received approximately three weeks ago, the Company now has sufficient financing to satisfy its requirement for immediate cash and complete the development of its NowCardio device.
Event Cardio Group Completes First $500,000 of $2,000,000 BreastCare DTS(TM) Distribution Agreement for Southern Asia
Marketwire Canada - Tue Apr 28, 3:00PM CDT
Event Cardio Group, Inc. (www.eventcardiogroup.com) (OTCQB: ECGI), a medical device company specializing in the detection and preventive treatment of high-risk diseases, is pleased to announce it has received the final $300,000 thereby completing the initial $500,000 stage of the $2,000,000 licensing agreement with MedPac Asia Pacific PTY Ltd, of Australia. MedPac received a Convertible Promissory Note and was granted the exclusive distribution rights for both BreastCare DTS(TM) and NowCardio(TM) products in their exclusive territory -- Australia, New Zealand, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Laos, Cambodia, Myanmar and Bangladesh. With the Philippines having the highest breast cancer mortality rate among the countries listed, the immediate focus will be to use pre-existing distribution channels to make the BreastCare DTS(TM) device available for consumers.
Event Cardio Group, Inc. Completes Next Step in Production of FDA-510k Cleared BreastCare DTS Device
Marketwired - Wed Apr 22, 3:00PM CDT
Event Cardio Group, Inc. (www.eventcardiogroup.com) (OTCQB: ECGI), a medical device company specializing in the detection and preventive treatment of high-risk diseases, is pleased to announce that Ceres Technologies, based in Saugerties, New York, (www.cerestechnologies.com) has begun manufacturing the BreastCare DTS(TM) device. With production of units underway the FDA Code of Federal Regulations Title 21 required filing for Good Manufacturing Practices is in process.
Event Cardio Group Signs $8,000,000 Investment Term Sheet With a Hong Kong Corporation
Marketwire Canada - Wed Mar 18, 3:00PM CDT
Event Cardio Group, Inc. (OTCQB: ECGI), a medical device company that specializes in the detection and preventive treatment of high-risk diseases, is pleased to announce it entered into an Investment Term Sheet with R.J. Capital Management, Ltd. The term Sheet calls for an investment of $4,000,000 for 20% of Event Cardio Group and an additional $4,000,000 contribution by R. J. Capital towards a joint venture which will have exclusive distribution and manufacturing rights for Event Cardio Group's FDA approved Breast Care DTS(TM) in China.
Event Cardio Group Closes First Tranche of $2,000,000 BreastCare DTS(TM) Distribution Agreement for Southern Asia
Marketwire Canada - Mon Mar 09, 3:00PM CDT
Event Cardio Group, Inc. (OTCQB: ECGI), a medical device company that specializes in the detection and preventive treatment of high-risk diseases, is pleased to announce it has completed the initial $500,000 stage of a $2,000,000 licensing agreement with MedPac Asia Pacific PTY Ltd, of Australia. MedPac invested $500,000 in Event Cardio Group for which it received a Convertible Promissory Note and was granted the exclusive distribution rights for both BreastCare DTS(TM) and NowCardio(TM) products in their exclusive territoriy -- Australia, New Zealand, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Laos, Cambodia, Myanmar and Bangladesh. With the Philippines having the highest breast cancer mortality rate among the countries listed, the immediate focus will be to use pre-existing distribution channels to make the BreastCare DTS(TM) device available for consumers.
Event Cardio Group Acquires Worldwide Rights to Now Cardio(TM), Advanced Cardiac Monitoring Device
Marketwired - Wed Nov 19, 4:10PM CST
Event Cardio Group, Inc. (OTCQB: ECGI), a medical device company, announced it has finalized its acquisition of full intellectual property (IP) and development rights for Now Cardio(TM), advanced cardiac monitoring device.
